S100A8 and neoplasm: MDSCs-secreted S100A8, which acts by destabilization of the tumor vasculature, represents a resistance-conferring factor induced by antiangiogenic therapies (AAT), which can be reverted by combining with ATRA through reduction of MDSCs levels (61).